Indoco Remedies inches up on entering into strategic distribution partnership with Clarity Pharma, UK
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Indoco Remedies is currently trading at Rs. 322.10, up by 0.10 points or 0.03% from its previous closing of Rs. 322.00 on the BSE.
The scrip opened at Rs. 338.00 and has touched a high and low of Rs. 353.80 and Rs. 312.30 respectively. So far 87041 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 416.95 on 01-Jan-2024 and a 52 week low of Rs. 286.50 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 353.80 and Rs. 297.80 respectively. The current market cap of the company is Rs. 2969.19 crore.
The promoters holding in the company stood at 58.75%, while Institutions and Non-Institutions held 19.94% and 21.30% respectively.
Indoco Remedies has entered into strategic distribution partnership with Clarity Pharma, UK. This partnership marks a significant milestone in Indoco’s history, as the company will launch around 20 products over the next 18 months through Clarity Pharma, its distributor in the UK. The Company will continue to supply all the products under existing B2B partnership to its clients.
Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company’s turnover is $212 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization. Clarity Pharma has over 25 years of experience in bringing products to market and now services over 4,000 Primary Healthcare customers.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
